Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023
SAN CARLOS, Calif., Sept. 10, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from a Phase 2 multicenter clinical trial evaluating sotigalimab (sotiga), Apexigen’s agonist antibody targeting CD40, in combination with neoadjuvant chemoradiation for patients with resectable esophageal and gastroesophageal junction (GEJ) cancers. Encouraging pathologic complete response (pCR) rates were observed in patients with both adenocarcinoma (AC) and squamous cell carcinoma (SCC). These data were featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress, being held both virtually and in Paris from September 9-13, 2022.
SAN CARLOS, Calif., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from a Phase 2 clinical trial evaluating sotigalimab (sotiga), Apexigen’s agonist antibody targeting CD40, in combination with neoadjuvant chemoradiation for patients with resectable esophageal and gastroesophageal junction (GEJ) cancers. These data will be featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress, being held both virtually and in Paris from September 9-13, 2022.
- Data from the Parker Institute for Cancer Immunotherapy and Cancer Research Institute multi-center Phase 2 PRINCE trial demonstrated that novel circulating and tumor biomarkers may be predictive of...
-The combination of intratumoral sotigalimab and systemic pembrolizumab induced broad innate and adaptive immune activation in local and distant tumors- -Oral presentation on April 12, 2022 at 3:35...
SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced new clinical data on sotigalimab in three poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, being held both virtually and in Washington, D.C., November 10-14, 2021. Sotigalimab, Apexigen’s lead immuno-oncology (I-O) therapeutic, is a potentially first-in-class and best-in-class CD40 agonist, with unique epitope specificity and Fc receptor engagement for optimal therapeutic effect and tolerability.